|
1
|
Al-Anbaki M, Cavin AL, Nogueira RC, Taslimi J, Ali H, Najem M, Shukur Mahmood M, Abdullah Khaleel I, Saad Mohammed A, Ramadhan Hasan H, Marcourt L, Félix F, Vinh Tri Low-Der’s N, Ferreira Queiroz E, Wolfender JL, Watissée M, Graz B. Hibiscus sabdariffa, a Treatment for Uncontrolled Hypertension. Pilot Comparative Intervention. Plants (Basel) 2021; 10:plants10051018. [PMID: 34069702 PMCID: PMC8160910 DOI: 10.3390/plants10051018] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 05/04/2021] [Accepted: 05/11/2021] [Indexed: 01/17/2023]
Abstract
In Iraq, in 2019, there were about 1.4 million Internally Displaced Persons (IDP); medical treatments were often interrupted. The feasibility of using Hibiscus sabdariffa (HS) decoction to curb hypertension was evaluated. A multicentric comparative pilot intervention for 121 participants with high blood pressure (BP) (≥140/90 mmHg) was conducted. Participants of the intervention group (with or without conventional medication) received HS decoction on a dose regimen starting from 10 grams per day. BP was measured five times over six weeks. The major active substances were chemically quantified. Results: After 6 weeks, 61.8% of participants from the intervention group (n = 76) reached the target BP < 140/90 mmHg, compared to 6.7% in the control group (n = 45). In the intervention group, a mean (±SD) reduction of 23.1 (±11.8) mmHg and 12.0 (±11.2) for systolic and diastolic BP, respectively, was observed, while in the control group the reduction was 4.4 (±10.2)/3.6 (±8.7). The chemical analysis of the starting dose indicated a content of 36 mg of total anthocyanins and 2.13 g of hibiscus acid. The study shows the feasibility of using HS decoction in IDP’s problematic framework, as hibiscus is a safe, local, affordable, and culturally accepted food product.
Collapse
Affiliation(s)
- Marwah Al-Anbaki
- Antenna Foundation, Avenue de la Grenade 24, 1207 Geneva, Switzerland; (A.-L.C.); (R.C.N.); (B.G.)
- Correspondence: ; Tel.: +41-76-285-55-75
| | - Anne-Laure Cavin
- Antenna Foundation, Avenue de la Grenade 24, 1207 Geneva, Switzerland; (A.-L.C.); (R.C.N.); (B.G.)
| | - Renata Campos Nogueira
- Antenna Foundation, Avenue de la Grenade 24, 1207 Geneva, Switzerland; (A.-L.C.); (R.C.N.); (B.G.)
| | - Jaafar Taslimi
- The Iraq Health Access Organization (“IHAO”), District 901, Abu Nawas ST, Baghdad, Iraq; (J.T.); (H.A.); (M.N.); (M.S.M.); (I.A.K.); (A.S.M.); (H.R.H.)
| | - Hayder Ali
- The Iraq Health Access Organization (“IHAO”), District 901, Abu Nawas ST, Baghdad, Iraq; (J.T.); (H.A.); (M.N.); (M.S.M.); (I.A.K.); (A.S.M.); (H.R.H.)
| | - Mohammed Najem
- The Iraq Health Access Organization (“IHAO”), District 901, Abu Nawas ST, Baghdad, Iraq; (J.T.); (H.A.); (M.N.); (M.S.M.); (I.A.K.); (A.S.M.); (H.R.H.)
| | - Mustafa Shukur Mahmood
- The Iraq Health Access Organization (“IHAO”), District 901, Abu Nawas ST, Baghdad, Iraq; (J.T.); (H.A.); (M.N.); (M.S.M.); (I.A.K.); (A.S.M.); (H.R.H.)
| | - Ibrahim Abdullah Khaleel
- The Iraq Health Access Organization (“IHAO”), District 901, Abu Nawas ST, Baghdad, Iraq; (J.T.); (H.A.); (M.N.); (M.S.M.); (I.A.K.); (A.S.M.); (H.R.H.)
| | - Abdulqader Saad Mohammed
- The Iraq Health Access Organization (“IHAO”), District 901, Abu Nawas ST, Baghdad, Iraq; (J.T.); (H.A.); (M.N.); (M.S.M.); (I.A.K.); (A.S.M.); (H.R.H.)
| | - Hasan Ramadhan Hasan
- The Iraq Health Access Organization (“IHAO”), District 901, Abu Nawas ST, Baghdad, Iraq; (J.T.); (H.A.); (M.N.); (M.S.M.); (I.A.K.); (A.S.M.); (H.R.H.)
| | - Laurence Marcourt
- School of Pharmaceutical Sciences, University of Geneva, CMU, Rue Michel Servet 1, 1211 Geneva 4, Switzerland; (L.M.); (F.F.); (N.V.T.L.-D.); (E.F.Q.); (J.-L.W.)
- Institute of Pharmaceutical Sciences of Western Switzerland (ISPSW), University of Geneva, CMU, Rue Michel Servet 1, 1211 Geneva 4, Switzerland
| | - Fabien Félix
- School of Pharmaceutical Sciences, University of Geneva, CMU, Rue Michel Servet 1, 1211 Geneva 4, Switzerland; (L.M.); (F.F.); (N.V.T.L.-D.); (E.F.Q.); (J.-L.W.)
- Institute of Pharmaceutical Sciences of Western Switzerland (ISPSW), University of Geneva, CMU, Rue Michel Servet 1, 1211 Geneva 4, Switzerland
| | - Nicolas Vinh Tri Low-Der’s
- School of Pharmaceutical Sciences, University of Geneva, CMU, Rue Michel Servet 1, 1211 Geneva 4, Switzerland; (L.M.); (F.F.); (N.V.T.L.-D.); (E.F.Q.); (J.-L.W.)
- Institute of Pharmaceutical Sciences of Western Switzerland (ISPSW), University of Geneva, CMU, Rue Michel Servet 1, 1211 Geneva 4, Switzerland
| | - Emerson Ferreira Queiroz
- School of Pharmaceutical Sciences, University of Geneva, CMU, Rue Michel Servet 1, 1211 Geneva 4, Switzerland; (L.M.); (F.F.); (N.V.T.L.-D.); (E.F.Q.); (J.-L.W.)
- Institute of Pharmaceutical Sciences of Western Switzerland (ISPSW), University of Geneva, CMU, Rue Michel Servet 1, 1211 Geneva 4, Switzerland
| | - Jean-Luc Wolfender
- School of Pharmaceutical Sciences, University of Geneva, CMU, Rue Michel Servet 1, 1211 Geneva 4, Switzerland; (L.M.); (F.F.); (N.V.T.L.-D.); (E.F.Q.); (J.-L.W.)
- Institute of Pharmaceutical Sciences of Western Switzerland (ISPSW), University of Geneva, CMU, Rue Michel Servet 1, 1211 Geneva 4, Switzerland
| | | | - Bertrand Graz
- Antenna Foundation, Avenue de la Grenade 24, 1207 Geneva, Switzerland; (A.-L.C.); (R.C.N.); (B.G.)
| |
Collapse
|